| Table 1. Cycle characteristics of IVF treatments in the study groups | |||
| Non-PGT (N=99) | PGT (N=97) | p-value | |
|---|---|---|---|
| GT ingredient FSH FSH+LH HP HMG |
22/26 (84.6%) 1/26 (3.8%) 3/26 (11.5%) |
20/30 (71.4%) 4/30 (14.3%) 4/30 (14.3%) |
NS |
| GT dose (units) | 1797.63±697.08, 1795 (700-3750) | 2338.8±1163.3, 2100 (900-6750) | 0.04 |
| Max. endometrial thickness (mm) | 10.1±1.8, 9.8 (5.6-15) | 9.8±2.1, 9.6 (5.7-15) | NS |
| Number of follicles >14 mm | 10.8±4, 10 (5-23) | 11.97±5.6, 11 (2-26) | NS |
| Number of retrieved oocytes | 11.5±4.2, 11 (5-19) | 16.5±8.2, 14 (1-41) | <0.01 |
| M2 | 10±3.7, 9 (4-17) | 13.6±7.2, 13 (0-36) | 0.01 |
| 2PN | 6.81±3.5, 6 (1-16) | 10.8±6, 10.5 (0-29) | <0.01 |
| Fertilization rate (%) | 66.8±21.7, 71.4 (25-100) | 77.4±16.7, 80.5 (25-100) | 0.04 |
| E2 max before OPU (pmol\L) | 2493.2±3057, 938 (256-11643) | 3353.7±3913.6, 1158 (125-15944) | NS |
| E2 on HCG day (pmol\L) | 2878.6±3372.2, 1215 (126-18350) | 2144.8±2031, 1427 (7-9784) | NS |
| P on HCG day (nmol\L) | 66.5±41.3, 48 (2.3->127) | 67.6±42.3, 54.7 (1.5-190) | NS |
| Blastocyst grade Good Fair Poor |
42/82 (51.2%) 39/82 (47.2%) 1/82 (1.2%) |
60/93 (64.5%) 28/93 (30.1%) 5/93 (5.3%) |
0.03 |
| Mild OHSS | 0 | 4/97 (4.1%) | NS |
| Hormonal support PV progesterone PO progesterone IM progesterone Mixed progesterone Other |
54 (54.5%) 5 (5.1%) 9 (9.1%) 4 (4%) 22 (22.2%) |
60 (61.9%) 10 (10.3%) 9 (9.3%) 5 (5.2%) 10 (10.3%) |
NS |
Note: Mean±SD, median (range) is shown for continuous variables, and percentages are shown for dichotomous variables.
E2 = estradiol, FSH = follicle stimulating hormone, GT =gonadotropin, HCG = human chorionic gonadotropin, HP HMG = highly purified human menopausal gonadotropin, IM = intramuscular, LH = luteinizing hormone, M2 = metaphase 2, NS = not significant, OHSS = ovarian hyperstimulation syndrome, OPU = ovum pick-up, P = progesterone, PN = pronuclei, PO = oral, PV = vaginal.